Boston, MA 06/18/2013 (wallstreetpr) – The share prices of Medivation Inc (NASDAQ:MDVN) had declined by 6.78 percent to close at $47.41 per share for the end of last trading session on Monday. The shares of the company had been trading in the range of $45.47 to $48.50 per share for the day, after opening at $48.03 per share. The shares of Medivation Inc (NASDAQ:MDVN) had recorded 52 week low price level at $40.81 per share and 52 week high price level at $59.24 per share.
Medivation Inc (NASDAQ:MDVN) is primarily focused on the development and commercialization of novel therapies with its advanced program XTANDI capsules being carried out in partnership with Astellas Pharma Inc. Further, this partnership is also extended for conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer.
The shares of Medivation Inc (NASDAQ:MDVN) had recently been trading at lower prices with very heavy trading volumes, which had made the bio pharmaceutical company to be added into the Growing Stock Reports’ NASDAQ decliners watch list. The company had witnessed the trade of 5.38 million shares on Monday, which is relatively higher compared to the average trading volume at 986,336 shares per day.
Medivation Inc (NASDAQ:MDVN) presently holds 74.98 million shares outstanding in the market with an institutional ownership of 97 percent of its holdings. The shares of the company are presently trading near their 52 week low price levels which had sent a cautious sentiment to the investors.
